The patent pending MyoVista™ i-ECG technology is a portable, inexpensive, diagnostic screening device used to determine the presence, level, and location of myocardial abnormalities. The MyoVista™ test is a quick, non-invasive procedure, producing complete results in 30 seconds.
Five years of testing, along with current Heart Test Laboratories clinical trials, have shown an average 90% or better correlation to an invasive angiogram with the MyoVista™ i-ECG technology.
The Primary Care Physician is the first line of detection in the identification of silent heart disease, and our product is for the masses, Says Drew Diaz, Heart Test Labs CEO. "It is not our intent to replace the angiogram, but to provide early screening to identify those patients that should be immediately sent to their Cardiologist for further assessment”. "We believe that literally hundreds of thousands of lives can be saved with this technology", says Diaz.
About The American College of Cardiology
The mission of the American College of Cardiology is to advocate for quality cardiovascular care—through education, research promotion, development and application of standards and guidelines—and to influence health care policy.
The College is a 37,000-member nonprofit medical society and bestows the credential Fellow of the American College of Cardiology upon physicians who meet its stringent qualifications. The College is a leader in the formulation of health policy, standards and guidelines, and is a staunch supporter of cardiovascular research. The ACC provides professional education and operates national registries for the measurement and improvement of quality care. www.acc.org
# # #
Heart Test Labs develops non-invasive screening devices for the Coronary Arterial Disease market. Their MyoVista™ i-ECG technology is an affordable device that determines the presence, level, and location of any myocardial abnormalities in 30 seconds.